Optomed Q2: Soft sales and important quarters ahead

Research Update

2024-08-09

07:00

Redeye provides an update following Optomed’s Q2 report. Although sales and EBIT came in lower than anticipated, we argue that the investment case remains intact. We highlight upcoming reports that may potentially show sales related to the US rollout of Aurora AEYE. Furthermore, we have made only minor estimate changes, leaving the fair value range unchanged.

Gustaf Meyer

Analyst Q&A

Closed

Gustaf Meyer answered 2 questions.

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.